T Cell News and Research

Latest T Cell News and Research

Immune checkpoint inhibitor target found to promote skin cancer growth

Programmed cell death 1 (PD-1) is an important target for immune checkpoint inhibitor therapies that block its signaling and boost T-cell activity. PD-1 inhibitors have been approved for treating various types of cancer.

19 Jan 2024

Study reveals intestinal helminth infection diminishes T cell response to COVID-19 mRNA vaccine

Study investigates the impact of helminth infection on COVID-19 mRNA vaccine efficacy, revealing that while antibody responses remain largely unaffected, T-cell responses are significantly impaired, particularly against Omicron variants.

17 Jan 2024

Innovative computational tool unearths hidden cancer targets for immunotherapy

An innovative computational tool dubbed "SNAF" may help the research world bring the emerging promise of cancer immunotherapy to a wider range of patients, according to a study published Jan. 17, 2024, in Science Translational Medicine.

17 Jan 2024

Decoding blood cancer secrets to optimize CAR T therapy

Chimeric antigen receptor T-cell therapy, or CAR T, has dramatically improved the treatment of certain blood cancers. Initially approved for patients who had failed multiple lines of therapy, clinical trials have shown CAR T can be used as an earlier treatment option.

17 Jan 2024

Study shows slight increase in Guillain-Barre syndrome risk with adenovirus COVID vaccines

Study investigates the link between COVID-19 vaccines and autoimmune/neurological diseases, focusing on Guillain-Barre syndrome (GBS) risks associated with adenovirus vector vaccines.

16 Jan 2024

Immune dysregulation in long COVID patients uncovered in new study

Sstudy reveals significant immune changes in long COVID patients, including altered T cell responses and systemic inflammation, using advanced 'omics' and serological assays.

14 Jan 2024

Study shows lasting T-cell immunity in healthcare workers against SARS-CoV-2 variants

Study reveals robust memory T-cell responses to SARS-CoV-2 in healthcare workers over 1.5 years post-Omicron, suggesting durable immunity against highly mutated variants.

11 Jan 2024

New intranasal vaccine candidate triggers powerful mucosal defense against SARS-CoV-2

A team of scientists, led by Duke-NUS Medical School, has discovered a potential intranasal vaccine candidate that provides improved, longer-lasting immunity against SARS-CoV-2 viruses compared to when given as an injection.

10 Jan 2024

Hidden identity of blood cancer revealed

Leukemia is a common term used to refer to a form of blood cancer. However, there are different types of leukemia depending on the cell type involved.

9 Jan 2024

Beckman coulter life sciences achieves industry-first with commercial release of anti-TRBC2 conjugated antibody for flow cytometry

Beckman Coulter Life Sciences, a global leader in laboratory automation and innovation, continues to lead the way with first-to-market concepts to help laboratories achieve goals faster and with greater accuracy.

From Beckman Coulter Life Sciences 9 Jan 2024

Study finds Epstein-Barr virus T-cells prevalent in early multiple sclerosis

A study led by UTHealth Houston reveals that T-cells specific for Epstein-Barr virus-infected cells are highly present in the cerebrospinal fluid of people with early-stage multiple sclerosis, suggesting a link between EBV and the disease.

8 Jan 2024

Are pan-coronavirus vaccines an achievable goal in providing broad protection against human coronaviruses?

The current achievements in the development of a pan-coronavirus vaccine.

3 Jan 2024

$Lisocabtagene maraleucel: A cost-effective second-line treatment for relapsed/refractory DLBCL$

Lisocabtagene maraleucel: A cost-effective second-line treatment for relapsed/refractory DLBCL

Lisocabtagene maraleucel (liso-cel), a CAR T-cell therapy, is a cost effective second line treatment for relapsed and refractory (hard to treat) diffuse large B-cell lymphoma (r/r DLBCL), according to a study published today in Blood Advances.

28 Dec 2023

New non-steroidal anti-inflammatory can inhibit the cytokine storm and preserve innate immunity

Very early in the COVID-19 pandemic clinical trials in patients hospitalized with COVID-19 confirmed that corticosteroids like dexamethasone reduced mortality, but they were harmful when applied at the first COVID-19 symptoms, due to the weakening of innate antiviral immunity, leading to delayed viral clearance and adverse outcomes in severe viral pneumonias.

28 Dec 2023

NIAID study identifies critical T-cell function missing in prior HIV vaccine candidates

An effective HIV vaccine may need to prompt strong responses from immune cells called CD8+ T cells to protect people from acquiring HIV, according to a new study from researchers at the National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health, and colleagues.

14 Dec 2023

Developing a virtual twin for personalized cancer treatment with CAR-T cell therapy

In recent years, cancer immunotherapies have established themselves as a further pillar of medical oncology alongside traditional treatment options (surgery, radiotherapy and chemotherapy).

13 Dec 2023

New optimized vaccine approach targets Hepatitis C virus variability

A method to design vaccines for highly variable viruses like the hepatitis C virus.

12 Dec 2023

Double punch for B-cell lymphomas: CAR T-cell innovation boosts efficacy, cuts toxicity

The Malaghan Institute of Medical Research in collaboration with Wellington Zhaotai Therapies Limited today announced results of its phase 1 dose escalation trial of a new third-generation anti-CD19 chimeric antigen receptor (CAR) T-cell therapy to be presented at the American Society of Hematology (ASH) Annual Meeting in San Diego on 11 December, 3pm.

11 Dec 2023

Combination of dasatinib and blinatumomab offers effective treatment for older Ph+ ALL patients

Older patients with Philadelphia chromosome-positive (Ph+) acute lymphoblastic leukemia (ALL) who were not good candidates for the standard treatment of intensive chemotherapy had a median overall survival (OS) of 6.5 years on an alternate regimen of dasatinib and blinatumomab.

11 Dec 2023

Phase I clinical trial of new CAR T cell therapy AT101 shows promising early responses

Early results from a Phase I clinical trial of AT101, a new CAR T cell therapy that uses a distinct binding mechanism to target CD19, show a 100 percent complete response (CR) rate at the higher dose levels studied in the trial, according to researchers from the University of Pennsylvania Perelman School of Medicine and Penn Medicine's Abramson Cancer Center.

11 Dec 2023

T Cell News and Research

Latest T Cell News and Research

Immune checkpoint inhibitor target found to promote skin cancer growth

Study reveals intestinal helminth infection diminishes T cell response to COVID-19 mRNA vaccine

Innovative computational tool unearths hidden cancer targets for immunotherapy

Decoding blood cancer secrets to optimize CAR T therapy

Study shows slight increase in Guillain-Barre syndrome risk with adenovirus COVID vaccines

Immune dysregulation in long COVID patients uncovered in new study

Study shows lasting T-cell immunity in healthcare workers against SARS-CoV-2 variants

New intranasal vaccine candidate triggers powerful mucosal defense against SARS-CoV-2

Hidden identity of blood cancer revealed

Beckman coulter life sciences achieves industry-first with commercial release of anti-TRBC2 conjugated antibody for flow cytometry

Study finds Epstein-Barr virus T-cells prevalent in early multiple sclerosis

Are pan-coronavirus vaccines an achievable goal in providing broad protection against human coronaviruses?

Lisocabtagene maraleucel: A cost-effective second-line treatment for relapsed/refractory DLBCL

New non-steroidal anti-inflammatory can inhibit the cytokine storm and preserve innate immunity

NIAID study identifies critical T-cell function missing in prior HIV vaccine candidates

Developing a virtual twin for personalized cancer treatment with CAR-T cell therapy

New optimized vaccine approach targets Hepatitis C virus variability

Double punch for B-cell lymphomas: CAR T-cell innovation boosts efficacy, cuts toxicity

Combination of dasatinib and blinatumomab offers effective treatment for older Ph+ ALL patients

Phase I clinical trial of new CAR T cell therapy AT101 shows promising early responses

Immunology eBook

Achieving and maintaining ISO 27001 and BS 10012 certifications

Expanding research and clinical options for children with cancer

Examining how pain could play a direct protective role in the gut

T Cell News and Research

Latest T Cell News and Research

Immunology eBook

Achieving and maintaining ISO 27001 and BS 10012 certifications

Expanding research and clinical options for children with cancer

Examining how pain could play a direct protective role in the gut

Newsletters you may be interested in